The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Glossary Glossary

Viramune (Nevirapine)

The Details

Viramune (nevirapine or NVP) is a non-nucleoside reverse transcriptase inhibitor used to treat HIV/AIDS. It is approved by the U.S. FDA for the treatment of HIV infection in adults and children 15 days and older.


Adult single dose: Take one 200-mg tablet once daily for the first 14 days, then take one 200-mg tablet twice daily.


  • The 14-day lead-in period must be strictly followed; it has been demonstrated to reduce the frequency of rash.
  • Monitoring during the first 18 weeks of therapy is essential. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of adverse events.
  • Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.
  • Viramune should not be started in women with over 250 CD4 cells or in men with over 400 CD4 cells due to the risk of liver problems.
  • Women should not breastfeed while on Viramune.
The Basics

  • Email Email
  • Glossary Glossary